Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05518864
Other study ID # 110130
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 21, 2021
Est. completion date October 21, 2024

Study information

Verified date February 2024
Source Radboud University Medical Center
Contact D.A.W. Janssen, MD PhD
Phone +31641856516
Email dick.janssen@radboudumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Efficacy study (RCT) for glycosaminoglycan(GAG)-therapy for the indication bladder pain syndrome / interstitial cystitis with Hunner lesion subtype (BPS-IC H+). reason for this study is a current lack of evidence regarding its efficacy and cost-effectiveness. Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain and Quality of Life (QOL)


Description:

Rationale: Reimbursement in the Netherlands for GAG-therapy for bladder pain syndrome / interstitial cystitis patients with Hunner lesion subtype (BPS-IC H+) is under debate, as evidence regarding its efficacy and cost-effectiveness is lacking. Objective: Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain. Secondary objectives are to determine the 1) cost-effectiveness of GAG therapy, 2) effectiveness of GAG therapy on quality of life and bladder inflammation evaluated by urethrocystoscopy Study design: Multi-design study. Study is powered and set-up as double-blinded randomized intervention study and is extended with a double-blinded aggregated N-of-1 trial. As requested by the Zorginstituut Netherlands, the study will be further extended with a prospective, non-blinded intervention study to evaluate long term follow up with a low frequency therapy dose. Study population: People with symptomatic BPS-IC H+ (> 18 yrs old). A total of 80 patients will be included for the main study. Intervention : GAG bladder instillations (hyaluronic acid + chondroitin sulfate; Ialuril) 50ml administered with a catheter. Placebo will be Hypromellose 50ml administered with a catheter. Patients will receive instillations (Ialuril / placebo with ratio 2:1) in 3 periods of 6 wks with frequency of 1 instillation/wk. With wash-out periods 4 wks. After 3 periods of treatment / placebo (wk 30), blinding will cease and continue unblinded where all subjects will receive maintenance therapy Ialuril for 1x/4wk until 54 weeks (endpoint). Main study parameters/endpoints: Primary outcome parameter: change from baseline in maximum bladder pain (visual analogue scale (VAS) pain score (3d average and maximal pain score). Secondary outcome parameters: - Change from baseline in VAS score (0-10) on self-reported secondary symptoms - Change from baseline from self-reported Global Assessment of Improvement (Likert scale) - Change from baseline from O'Leary-Sant IC Symptom Index & Problem Index questionnaire - Change from baseline in urethrocystoscopic evaluation of bladder mucosa (inflammation, active Hunner lesions) (clinician assessed estimated % of inflammation & degree of inflammation) - Change from baseline in Quality of Life using ED-5D 5L questionnaire (Dutch) - Cost effectiveness analyses using iMCQ and iPCQ questionnaires - Changes in Patient Reported Outcome questionnaire (incl. urinary frequency) - Adverse events using Clavien-Dindo system Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Benefits patients and group relatedness. All participants are capacitated adults and will receive a similar amount of intervention and placebo treatments. Treatment corresponds to the Dutch NVU guideline BPS. Therapy will be reimbursed for patients. During 54wks, patients will have a 6 week period where placebo is given. Due to the study design, patients can obtain a personal (individual) study efficacy result if therapy was successful in him/her. Therapy and placebo: risks and burden This study will be submitted as low-intervention trial. GAG therapy (instillations) has been used for >25 yrs in clinical practice to treat BPS-IC. GAG-therapies are registered as medical devices. The therapy is instilled into the bladder using a catheter (by nurse / patient). Catherization has a small increased risk for developing an urine tract infection (1.9%) [Herr 2015], urethral discomfort and in rare cases urethral trauma. The placebo compound Hypromellose 0.3% is used as moisturizing drops to treat dry eyes. It is inert (non-irritating and hypo-allergenic). Very rare (< 0.01%) side effects are reported in the Dutch 'Farmacologisch Kompas'. They report local side effects of sensitivity (burning, itch, tears e.d.). Blurry vision. and very rare systemic effects as rash, itch.Because of these reported side effects at inclusion the (over)sensitivity is checked by one drop in an eye, taking into account the possible blurry vision afterwards.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date October 21, 2024
Est. primary completion date October 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult patients (18 yrs or older) with symptomatic BPS with established Hunner lesions objectified with urethrocystoscopy in the 3 months prior to inclusion. 2. A VAS pain score (maximum pain during the last 3 days; scale 0-10) of at least 4. Exclusion Criteria: 1. pain, discomfort in pelvic region of inflammatory bladder conditions due to any cause other than BPS with Hunner lesions, with the exception of irritable bowel syndrome (IBS) and hypertonic pelvic floor or urine tract infections (UTI; <3 UTI's / year). This is noted by ESSIC as a confusable disease [van de Merwe 2007, contains an elaborate table for this]. 2. had a urine tract infection in the previous 6 weeks. 3. received bladder instillations for BPS in the previous 3 months; 4. received intradetrusor Botulinum toxin (BOTOX) injections within the previous 12 months. 5. received transurethral coagulation/ablation therapy of Hunner lesions within the last 12 months, with the exception of patients who have objectified Hunner lesion recurrence(s) on cystoscopy after coagulation/ablation therapy after at least 3 months' post-intervention. 6. started a new treatment for (chronic) pain (pharmacotherapy) or urine tract infection in the last month. 7. Unable (also legal) to give informed consent. 8. Allergic to Hypromellose (tested in one eye)

Study Design


Intervention

Device:
IALURIL Prefill
GAG therapy (bladder instillations with glycosaminoglycans)

Locations

Country Name City State
Netherlands Rijnstate Arnhem
Netherlands Andros Clinics Baarn
Netherlands Slingeland Doetinchem
Netherlands Catharina ziekenhuis Eindhoven
Netherlands Alrijne ziekenhuis Leiden
Netherlands MUMC+ Maastricht
Netherlands Radboud Unviversity Nijmegen Medical Centre Nijmegen Gelderland
Netherlands Isala klinieken Zwolle

Sponsors (5)

Lead Sponsor Collaborator
Radboud University Medical Center IQ Healthcare, Radboud Technology Ceter, ZonMw: The Netherlands Organisation for Health Research and Development, Zorginstituut Nederland

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in maximum bladder pain VAS pain score (0-10; 0= no pain, 10=worst pain) Fase 1: Week 1,2,5,7,8,12,15,17,18,22,25,27,28,29 Fase 2:week 32, 36, 40, 44, 48, 54
Secondary Change in average bladder pain VAS pain score (0-10; 0= no pain, 10=worst pain) Fase 1: Week 1,2,5,7,8,12,15,17,18,22,25,27,28,29 Fase 2:week 32, 36, 40, 44, 48, 54
Secondary 7-point Global Response Assessment (GRA) scale The GRA is a 7-point descriptive scale, scores of 1-3 indicate worsening of symptoms, and 5-7 indicate and improvement in symptoms Fase 1: Week 1,2,5,7,8,12,15,17,18,22,25,27,28,29 Fase 2:week 32, 36, 40, 44, 48, 54
Secondary Change in patient assessed most dominant symptom VAS score (0-10; 0= no burden, 10=high burden) Fase 1: Week 1,2,5,7,8,12,15,17,18,22,25,27,28,29 Fase 2:week 32, 36, 40, 44, 48, 54
Secondary Voiding urgency as single item from the validated Genito-Urinary Pain Index questionnaire (5 point Likert scale) Fase 1: Week 1,2,5,7,8,12,15,17,18,22,25,27,28,29 Fase 2:week 32, 36, 40, 44, 48, 54
Secondary Voiding frequency as single item from the validated Genito-Urinary Pain Index questionnaire (5 point Likert scale) Fase 1: Week 1,2,5,7,8,12,15,17,18,22,25,27,28,29 Fase 2:week 32, 36, 40, 44, 48, 54
Secondary O'leary Sant interstitial cystitis symptom index/problem index (ICSI/ICPI) Validated BPS-IC related symptom questionaire week 1, 6, 18, 28, 29, 40, 48
Secondary Patient Reported Outcome Measurement (PROM) short and extended Improvement (0-100%), continue treatment, reccommend to family, including Adverse Events and start/stop other treatment for BPS/IC week 1, 8, 18, 28, 29, 40, 48
Secondary Voiding diary 2x24h at baseline
Secondary Quality of Life questionnaire Outcome of ED-5D 5L QoL questionnaire week 1, 6, 18, 28, 29, 40, 48
Secondary Urine sediment Screening for bacterial urinary tract infection week 1, 6, 18, 28, 29, 40, 48
Secondary Cost effectiveness iMCQ and iPCQ questionaires week 1, 8, 18, 28
Secondary Cystoscopic evaluation Likert scale inflammation (1-5) week 8 and week 28
See also
  Status Clinical Trial Phase
Completed NCT04313972 - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone Phase 4
Completed NCT03282318 - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Phase 2
Terminated NCT02591199 - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT04401176 - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT04001244 - Translational Research in Pelvic Pain
Suspended NCT04450316 - Low-dose Naltrexone for Bladder Pain Syndrome Phase 2
Completed NCT04010513 - Hypnosis for Bladder Pain Syndrome N/A
Active, not recruiting NCT05414305 - The Female Microbiome in Patients Undergoing Bladder Instillation Therapy Phase 2
Withdrawn NCT03027076 - Microbiome of Urologic Chronic Pelvic Pain Syndrome N/A
Terminated NCT01879930 - Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Phase 4
Recruiting NCT05155384 - Biopsychosocial and Conventional Approach in Bladder Pain Syndrome N/A
Recruiting NCT05737121 - Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS Phase 2
Recruiting NCT05699551 - Supervised Exercise as a Therapeutic Strategy for Interstitial Cystitis/Bladder Pain Syndrome N/A
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT04821882 - Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis N/A
Completed NCT04208087 - PK and Safety of SI-722 in IC/BPS Phase 1/Phase 2
Recruiting NCT05740007 - A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Recruiting NCT03076762 - Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Phase 2
Active, not recruiting NCT04789135 - Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis /Bladder Pain Syndrome Phase 2
Recruiting NCT04118946 - Platelet Enriched Plasma for Treatment of Interstitial Cystitis Phase 1/Phase 2